Patents by Inventor Gerhard Steinmann

Gerhard Steinmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage regimens for HCV combination therapy
    Patent number: 8822496
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carla Haefner, Gerhard Steinmann, Jerry O. Stern, Chan-Loi Yong
  • DOSAGE REGIMENS FOR HCV COMBINATION THERAPY
    Publication number: 20110268700
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 3, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carla HAEFNER, Gerhard STEINMANN, Jerry O. STERN, Chan-Loi YONG
  • Potent inhibitor of HCV serine protease
    Publication number: 20040138109
    Abstract: Disclosed are oral pharmaceutical compositions, kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein the following Compound (1), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range: 1
    Type: Application
    Filed: September 16, 2003
    Publication date: July 15, 2004
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & CO. KG
    Inventors: Shirlynn Chen, Jens Oliver Croenlein, Gerhard Nehmiz, Gerhard Steinmann, Jocelyn Abella Gunn, Phuong Do Costa